Sponsorship from Gilead
The executive committee of the Fondation Lucien-Piché is proud to announce the addition of Gilead to its list of sponsors. We would like to acknowledge them for their generous contribution and for supporting the training of the next generation of highly qualified chemists in the province of Quebec.
Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. With each new discovery and investigational drug candidate, we seek to improve the care of patients living with life-threatening diseases around the world. Gilead’s therapeutic areas of focus include HIV/AIDS, liver diseases, hematology and oncology, inflammatory and respiratory diseases and cardiovascular conditions. Since its founding in Foster City, California, in 1987, Gilead has become a leading biopharmaceutical company with a rapidly expanding product portfolio, a growing pipeline of investigational drugs and over 8,900 employees in offices across six continents. Millions of people around the world are living healthier lives because of innovative therapies developed by Gilead. Today, our research and development effort includes more than 200 ongoing clinical studies evaluating compounds with the potential to become the next generation of effective medicines. Gilead's manufacturing facility in Edmonton, Alberta, is responsible for the development and manufacturing of investigational drugs. We supply active pharmaceutical ingredients for clinical research programs and contribute supplies for new product launches.
About the Fondation Lucien-Piché:
The Fondation Lucien-Piché is a charitable non-profit registered organization which supports outstanding students in chemistry across the province of Quebec. Every year, the Foundation awards scholarships to the best finishing students enrolled in undergraduate chemistry programs. Since its creation in 1987, the Foundation has awarded more than 120 scholarships for a total of more than 100,000$.